Seeing Is Believing
Currently out of the existing stock ratings of Jason Gerberry, 152 are a BUY (64.68%), 56 are a HOLD (23.83%), 27 are a SELL (11.49%).
Analyst Jason Gerberry, currently employed at BAML, carries an average stock price target met ratio of 60.56% that have a potential upside of 27.64% achieved within 255 days.
Jason Gerberry’s has documented 498 price targets and ratings displayed on 47 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on LLY, Eli Lilly and Company at 10-Dec-2024.
Analyst best performing recommendations are on CORI (CORIUM INTERNATIONAL).
The best stock recommendation documented was for KRTX (KARUNA THERAPEUTICS) at 8/9/2022. The price target of $261 was fulfilled within 2 days with a profit of $32.55 (14.25%) receiving and performance score of 71.24.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$191
$16.81 (9.65%)
10 days ago
(10-Dec-2024)
3/4 (75%)
$15.34 (8.73%)
764
Hold
$191
$16.81 (9.65%)
$205
10 days ago
(10-Dec-2024)
2/4 (50%)
$15.34 (8.73%)
507
Hold
$206
$31.81 (18.26%)
$153
28 days ago
(22-Nov-2024)
13/14 (92.86%)
$27.92 (15.68%)
293
Buy
$200
$25.81 (14.82%)
$190
1 months 7 days ago
(13-Nov-2024)
12/13 (92.31%)
$28.57 (16.67%)
490
Buy
$215
$40.81 (23.43%)
$226
1 months 8 days ago
(12-Nov-2024)
8/10 (80%)
$39.86 (22.76%)
293
Which stock is Jason Gerberry is most bullish on?
Which stock is Jason Gerberry is most reserved on?
What Year was the first public recommendation made by Jason Gerberry?